Faeth Therapeutics, Inc
Analysis Terminal
AI Sector Synthesis
Faeth Therapeutics (FTH) recently received a 'Buy' initiation due to anticipated catalysts from its PIKTOR cancer program through 2027 and a $200 million capital raise, though dilution risk was noted. Additionally, the company announced the appointment of Karen Vousden, Ph.D., to its Board of Directors, effective September 11, 2026.
Latest Market News
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion
Initiate Faeth Therapeutics (FTH) at Buy: PIKTOR cancer program catalysts through 2027, $200M raise boosts runway but dilution risk.
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
AUSTIN, Texas, September 17, 2026--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.
Faeth Therapeutics, Inc is a leading entity in the Biotechnology sector, headquartered in US.
Professional Notice
Information is for educational purposes only. Market data is sourced via global nodes and is not financial advice.